Education
About Us
Working with TipRanks
Follow Us
Allovir Inc (ALVR)
NASDAQ:ALVR
ALVR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.96 - $24.15
Previous CloseN/A
Volume83.88K
Average Volume (3M)N/A
Market Cap
$30.20M
Enterprise ValueN/A
Total Cash (Recent Filing)$118.29M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.85
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.75
Shares Outstanding5,043,357
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)9.81
Price to Sales (P/S)N/A
P/FCF Ratio-0.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
AlloVir News
PremiumCompany Announcements
AlloVir Merges with Kalaris Therapeutics, Inc.
PremiumCompany Announcements
AlloVir Stockholders Approve Key Amendment and Merger
PremiumCompany Announcements
AlloVir Appoints Vikas Sinha as New CEOPremiumCompany Announcements
AlloVir and Kalaris Merge to Advance Retinal TherapiesOwnership Overview
Currently, No data available
---
ALVR FAQ
What was Allovir Inc’s price range in the past 12 months?
Allovir Inc lowest stock price was $7.96 and its highest was $24.15 in the past 12 months.
What is Allovir Inc’s market cap?
Allovir Inc’s market cap is $30.20M.
When is Allovir Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Allovir Inc’s earnings last quarter?
Currently, no data Available
Is Allovir Inc overvalued?
According to Wall Street analysts Allovir Inc’s price is currently Overvalued.
Does Allovir Inc pay dividends?
Allovir Inc does not currently pay dividends.
What is Allovir Inc’s EPS estimate?
Allovir Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Allovir Inc have?
Allovir Inc has 5,043,357 shares outstanding.
What happened to Allovir Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Allovir Inc?
Currently, no hedge funds are holding shares in ALVR
AlloVir Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Increased
By 19.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.6%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
-45.37%
Trailing 12-Months
Asset Growth
-37.87%
Trailing 12-Months
Company Description
Allovir Inc
AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
Sangamo Biosciences
―
Bluebird Bio
―
Fate Therapeutics
―
Iovance Biotherapeutics
―
Adaptimmune Therapeutics
―